Mostrando 1 - 2 Resultados de 2, tiempo de consulta: 0.06s Limitar resultados
  1. 1
    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC por Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S, McInnes, I

    Publicado 2021
    Conference item
  2. 2
    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC por Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S, McInnes, I

    Publicado 2022
    Journal article

Herramientas de búsqueda: